PubMed · 12833654
CDP-870. Celltech/Pfizer.
Abstract
Celltech Group plc (formerly Celltech Chiroscience), in collaboration with Pfizer Inc (formerly Pharmacia Corp), is developing CDP-870, a polyethylene glycol (PEG)ylated anti-TNF antibody fragment, for the potential treatment of certain autoimmune and inflammatory diseases, including rheumatoid arthritis (RA) and Crohn's disease (CD). In October 2002, Pharmacia initiated phase III trials for RA and at this time Celltech anticipated initiating phase III trials for CD in mid-2003.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Stefan Rose-John, Heidi Schooltink. 2003. CDP-870. Celltech/Pfizer.. https://pubmed.ncbi.nlm.nih.gov/12833654/
Cite the original work for its findings. Save a collection to share your selection of sources.